GlassScriptPhysician profile
Stephen M Durso
NPI 1023128675
$4,159.17
in general payments reported to CMS, 2019-2025
38 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $300 · 2021: $804 · 2022: $862 · 2023: $781 · 2024: $500 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.83 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Mayne Pharma Commercial LLC | $455.46 | 2021-2025 | |
| Astellas Pharma US INC | $374.17 | 2023-2025 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $313.05 | 2021 | |
| Pfizer INC. | $211.44 | 2019-2025 | |
| Shield Therapeutics INC | $210.34 | 2023-2025 | |
| Exeltis, USA INC. | $145.40 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $143.30 | 2020-2022 | |
| Coopersurgical, INC. | $141.61 | 2019-2021 | |
| Aspira Women'S Health INC | $131.56 | 2021-2022 | |
| Hologic Sales and Service, LLC | $125.79 | 2019-2024 | Aptima |
| Evofem Biosciences, INC. | $113.02 | 2021-2023 | Phexxi |
| Sumitomo Pharma America, INC. | $103.54 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $94.09 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $90.59 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $80.17 | 2022-2025 | Nexplanon, Jada System |
| Novo Nordisk INC | $65.57 | 2023-2025 | Wegovy |
| Myovant Sciences INC. | $62.54 | 2021-2022 | |
| Medline Industries LP | $62.21 | 2022-2024 | |
| Allergan, INC. | $52.92 | 2019-2020 | |
| Agile Therapeutics, INC. | $46.77 | 2021-2023 | Twirla |
| Duchesnay USA Incorporated | $44.75 | 2019 | |
| Baxter Healthcare | $44.34 | 2022-2023 | Tisseel |
| Daiichi Sankyo INC. | $40.13 | 2019-2021 | |
| Roche Diagnostics Corporation | $38.52 | 2019-2020 | |
| Optumhealth Care Solutions, LLC | $34.45 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Bayer Healthcare Pharmaceuticals INC. | $29.03 | 2019-2020 | |
| Avion Pharmaceuticals | $28.36 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $23.64 | 2019 | |
| Millicent US INC | $22.01 | 2025 | Intrarosa, Femlyv |
| Scynexis, INC. | $18.99 | 2022 | |
| Covidien LP | $17.68 | 2019 | |
| Sage Therapeutics, LLC | $17.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2020 | |
| Lsi Solutions INC | $15.12 | 2023 | Fornisee |
| Minerva Surgical, INC | $12.04 | 2019 | |
| Lupin INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Durso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.